PE20170936A1 - NOVEL IMIDAZOPYRIDAZINE COMPOUNDS AND THEIR USE - Google Patents

NOVEL IMIDAZOPYRIDAZINE COMPOUNDS AND THEIR USE

Info

Publication number
PE20170936A1
PE20170936A1 PE2017000461A PE2017000461A PE20170936A1 PE 20170936 A1 PE20170936 A1 PE 20170936A1 PE 2017000461 A PE2017000461 A PE 2017000461A PE 2017000461 A PE2017000461 A PE 2017000461A PE 20170936 A1 PE20170936 A1 PE 20170936A1
Authority
PE
Peru
Prior art keywords
heteroaryl
optionally substituted
amino
alkyl
refers
Prior art date
Application number
PE2017000461A
Other languages
Spanish (es)
Inventor
Wei-Guo Su
Guangxiu Dai
Weihan Zhang
Wei Deng
Original Assignee
Hutchison Medipharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hutchison Medipharma Ltd filed Critical Hutchison Medipharma Ltd
Publication of PE20170936A1 publication Critical patent/PE20170936A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Se refiere a un derivado de imidazopiridazina de formula (I) en donde Ar es arilo o heteroarilo opcionalmente sustituido; W es heteroarilo o N(R3)heteroarilo opcionalmente sustituido; R1 es H, halo, -CN, entre otros; R2 es H, C1-C6 alquilo o C3-C8 cicloalquilo, opcionalmente sustituidos; R3 es H o C1-C6 alquilo; m es 1 o 2. Es un compuesto seleccionado: 4-amino-6-((1-(6-fenilimidazo[1, 2-b]piridazin-7-il)etil)amino)pirimidina-5-carbonitrilo, entre otros. Tambien se refiere a una composicion que lo comprende. Dicho compuesto es un inhibidor de la enzima fosfatidilinositol-3-cinasa (PI3K), siendo util en el tratamiento de enfermedades inflamatorias, autoinmunitarias o cancerIt refers to an imidazopyridazine derivative of formula (I) wherein Ar is optionally substituted aryl or heteroaryl; W is heteroaryl or optionally substituted N (R3) heteroaryl; R1 is H, halo, -CN, among others; R2 is H, C1-C6 alkyl or C3-C8 cycloalkyl, optionally substituted; R3 is H or C1-C6 alkyl; m is 1 or 2. It is a selected compound: 4-amino-6 - ((1- (6-phenylimidazo [1,2-b] pyridazin-7-yl) ethyl) amino) pyrimidine-5-carbonitrile, among others . It also refers to a composition that comprises it. This compound is an inhibitor of the enzyme phosphatidylinositol-3-kinase (PI3K), being useful in the treatment of inflammatory, autoimmune diseases or cancer.

PE2017000461A 2014-09-24 2015-09-23 NOVEL IMIDAZOPYRIDAZINE COMPOUNDS AND THEIR USE PE20170936A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201410494483.5A CN105503877A (en) 2014-09-24 2014-09-24 Imidazopyridazine compound and application thereof

Publications (1)

Publication Number Publication Date
PE20170936A1 true PE20170936A1 (en) 2017-07-13

Family

ID=55580324

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2017000461A PE20170936A1 (en) 2014-09-24 2015-09-23 NOVEL IMIDAZOPYRIDAZINE COMPOUNDS AND THEIR USE

Country Status (32)

Country Link
US (2) US10208066B2 (en)
EP (1) EP3197898B1 (en)
JP (1) JP6381792B2 (en)
KR (2) KR102111570B1 (en)
CN (2) CN105503877A (en)
AR (1) AR101964A1 (en)
AU (1) AU2015320142B2 (en)
BR (1) BR112017006002B1 (en)
CA (1) CA2958671C (en)
CL (1) CL2017000682A1 (en)
CY (1) CY1122763T1 (en)
DK (1) DK3197898T3 (en)
EA (1) EA032643B1 (en)
ES (1) ES2765510T3 (en)
HR (1) HRP20192279T1 (en)
HU (1) HUE047377T2 (en)
IL (1) IL250703B (en)
LT (1) LT3197898T (en)
MX (1) MX2017003902A (en)
MY (1) MY178136A (en)
NZ (1) NZ729886A (en)
PE (1) PE20170936A1 (en)
PH (1) PH12017500564B1 (en)
PL (1) PL3197898T3 (en)
PT (1) PT3197898T (en)
RS (1) RS59831B1 (en)
SG (1) SG11201701545YA (en)
SI (1) SI3197898T1 (en)
TW (1) TWI707855B (en)
UA (1) UA118066C2 (en)
WO (1) WO2016045591A1 (en)
ZA (1) ZA201701312B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105503877A (en) * 2014-09-24 2016-04-20 和记黄埔医药(上海)有限公司 Imidazopyridazine compound and application thereof
CN109516973A (en) * 2017-09-19 2019-03-26 南京圣和药业股份有限公司 Substituted uracil compound, preparation method and the usage
CN110386937A (en) * 2018-04-20 2019-10-29 和记黄埔医药(上海)有限公司 The crystal form of compound and unformed
CA3124013A1 (en) 2018-12-20 2020-06-25 Bayer Aktiengesellschaft Heterocyclyl pyridazine as fungicidal compounds
CN110028502B (en) * 2019-05-29 2020-02-14 济南周行医药科技有限公司 Preparation method of kinase inhibitor drug intermediate
CN115955916A (en) 2020-06-18 2023-04-11 拜耳公司 Active compound combinations
CN114031558A (en) * 2021-12-14 2022-02-11 无锡捷化医药科技有限公司 Preparation method of 1- (6-chloropyridazin-4-yl) ethyl-1-ketone
CN118159524A (en) * 2022-01-28 2024-06-07 和记黄埔医药(上海)有限公司 Synthesis method of intermediate of imidazo [1,2-b ] pyridazine compound

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773958A (en) 1997-01-03 1998-06-30 Ovonic Battery Company, Inc. Apparatus for detecting cell reversal in rechargeable batteries
EP0979231B1 (en) * 1997-04-25 2004-11-24 Takeda Chemical Industries, Ltd. Condensed pyridazine derivatives, their production and use
ES2605792T3 (en) 2004-05-13 2017-03-16 Icos Corporation Quinazolinone used as a human phosphatidylinositol 3-kinase delta inhibitor
US8097617B2 (en) 2006-03-31 2012-01-17 Novartis Ag Organic compounds
EP2079744A1 (en) 2006-10-30 2009-07-22 Novartis AG Imidazopyridazines as pi3k lipid kinase inhibitors
CN101522682A (en) 2006-10-30 2009-09-02 诺瓦提斯公司 Heterocyclic compounds as antiinflammatory agents
CN101528748A (en) * 2006-10-30 2009-09-09 诺瓦提斯公司 Imidazopyridazines as PI3K lipid kinase inhibitors
WO2008138834A1 (en) * 2007-05-09 2008-11-20 Novartis Ag Substituted imidazopyridazines as pi3k lipid kinase inhibitors
WO2009060197A1 (en) * 2007-11-08 2009-05-14 Centro Nacional De Investigaciones Oncologicas (Cnio) Imidazopyridazines for use as protein kinase inhibitors
PE20091268A1 (en) 2007-12-19 2009-09-19 Amgen Inc HETEROCYCLIC DERIVATIVES AS PI3 KINASE INHIBITORS
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
WO2010007099A1 (en) * 2008-07-15 2010-01-21 Cellzome Limited 2-aminoimidazo[1,2-b]pyridazine derivatives as pi3k inhibitors
WO2010057048A1 (en) 2008-11-13 2010-05-20 Calistoga Pharmaceuticals Inc. Therapies for hematologic malignancies
WO2012116237A2 (en) * 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
WO2013052699A2 (en) * 2011-10-04 2013-04-11 Gilead Calistoga Llc Novel quinoxaline inhibitors of pi3k
WO2013082540A1 (en) 2011-12-02 2013-06-06 Gilead Calistoga Llc Compositions and methods of treating a proliferative disease with a quinazolinone derivative
WO2013090725A1 (en) * 2011-12-15 2013-06-20 Philadelphia Health & Education Corporation NOVEL PI3K p110 INHIBITORS AND METHODS OF USE THEREOF
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
US20140120060A1 (en) 2012-11-01 2014-05-01 Infinity Pharmaceuticals, Inc. Treatment of rheumatoid arthritis and asthma using pi3 kinase inhibitors
US20140120083A1 (en) 2012-11-01 2014-05-01 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
TWI574962B (en) 2012-11-14 2017-03-21 加拓科學公司 Heteroaromatic compounds as pi3 kinase modulators and methods of use
AU2013364070B2 (en) 2012-12-21 2016-10-27 Gilead Calistoga Llc Isoquinolinone or quinazolinone phosphatidylinositol 3-kinase inhibitors
CN105503877A (en) * 2014-09-24 2016-04-20 和记黄埔医药(上海)有限公司 Imidazopyridazine compound and application thereof

Also Published As

Publication number Publication date
MY178136A (en) 2020-10-05
CA2958671C (en) 2019-04-30
EA201790276A1 (en) 2017-10-31
CN105503877A (en) 2016-04-20
KR20170048598A (en) 2017-05-08
CA2958671A1 (en) 2016-03-31
US10208066B2 (en) 2019-02-19
TW201612181A (en) 2016-04-01
TWI707855B (en) 2020-10-21
IL250703A0 (en) 2017-04-30
WO2016045591A1 (en) 2016-03-31
US10611777B2 (en) 2020-04-07
US20170253618A1 (en) 2017-09-07
PH12017500564A1 (en) 2017-08-30
ES2765510T3 (en) 2020-06-09
CN106715432A (en) 2017-05-24
BR112017006002B1 (en) 2023-02-14
MX2017003902A (en) 2017-12-07
EP3197898A1 (en) 2017-08-02
LT3197898T (en) 2020-02-10
CY1122763T1 (en) 2021-03-12
SG11201701545YA (en) 2017-04-27
DK3197898T3 (en) 2020-01-20
JP2017528500A (en) 2017-09-28
EP3197898A4 (en) 2018-03-14
SI3197898T1 (en) 2020-03-31
HRP20192279T1 (en) 2020-03-06
EA032643B1 (en) 2019-06-28
EP3197898B1 (en) 2019-11-27
AU2015320142B2 (en) 2018-02-15
PH12017500564B1 (en) 2017-08-30
NZ729886A (en) 2020-06-26
CN106715432B (en) 2019-03-26
KR102006670B1 (en) 2019-10-01
PT3197898T (en) 2020-01-17
KR20190090065A (en) 2019-07-31
IL250703B (en) 2020-09-30
KR102111570B1 (en) 2020-05-18
ZA201701312B (en) 2019-06-26
BR112017006002A2 (en) 2017-12-19
PL3197898T3 (en) 2020-06-29
CL2017000682A1 (en) 2017-10-30
AU2015320142A1 (en) 2017-04-27
US20190127391A1 (en) 2019-05-02
JP6381792B2 (en) 2018-08-29
AR101964A1 (en) 2017-01-25
UA118066C2 (en) 2018-11-12
RS59831B1 (en) 2020-02-28
HUE047377T2 (en) 2020-04-28

Similar Documents

Publication Publication Date Title
PE20170936A1 (en) NOVEL IMIDAZOPYRIDAZINE COMPOUNDS AND THEIR USE
PE20191613A1 (en) PYRAZOLE [1,5-A] PYRIDINE COMPOUNDS SUBSTITUTED AS INHIBITORS OF RET KINASE
CL2017001426A1 (en) New compounds of 3-substituted 5-amino-6h-thiazolo [4,5-d] pyrimidin-2,7-dione for the treatment and prophylaxis of viral infections.
MX2018015422A (en) [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds.
PH12016502504A1 (en) Mnk inhibitors and methods related thereto
MX2020009887A (en) Aminopyrimidine derivatives as ctps1 inhibitors.
CL2012001821A1 (en) Compounds derived from 5-alkynyl-pyrimidines, kinase inhibitors; pharmaceutical compositions containing them; and its use for the treatment and / or prevention of cancer, infections, inflammatory and autoimmune diseases.
MA39172B1 (en) Heterocyclic bicyclic derivatives as bromodomaine inhibitors
EA201791563A1 (en) SUBSTITUTED NUCLEOSIDE DERIVATIVES, USEFUL AS AN AGENT AGAINST CANCER
EA201400333A1 (en) BENZONITRIL DERIVATIVES AS KINAZ INHIBITORS
PE20161427A1 (en) SYK HETEROARYL INHIBITORS
PE20190656A1 (en) TIAZOLO-PYRIDINE COMPOUNDS REPLACED AS INHIBITORS OF MALT1
EA201790395A1 (en) AMINOTRIAZIN DERIVATIVES SUITABLE FOR USING AS TANK-BINDING KINASE INHIBITORS
PE20211782A1 (en) COMPOSITIONS OF 5-CHLORO-2-DIFLUOROMETOXIFENIL PYRAZOLOPYRIMIDINE, COMPOSITIONS AND METHODS OF USE OF THE SAME
EA201591591A1 (en) COMPOUNDS OF CARBAZOLE APPLIED AS Bromodomain Inhibitors
PH12015502041B1 (en) Heteroaryl compounds and uses thereof
CR20210265A (en) Aminopyrimidine/pyrazine derivatives as ctps1 inhibitors
PE20180024A1 (en) TRIAZOLOPYRAZINONES AS PDE1 INHIBITORS
WO2019035863A8 (en) Pyruvate kinase activators for use in treating blood disorders
CL2009000429A1 (en) Compounds derived from fused carbamoyl-heterocycles, especially pyrrolo [3,2-c] pyridine-2-carboxamides, smo inhibitors; pharmaceutical composition comprising said compounds; and use in the prophylaxis or treatment of cancer.
MA38982A1 (en) Novel octahydro-cyclobuta [1,2-c; 3,4-c '] dipyrrol-2-yl
UY32432A (en) FUSIONED PYRIMIDINE COMPOUNDS AS AKT INHIBITORS
CL2017002856A1 (en) Thioether compounds as nitrification inhibitors
SG195319A1 (en) Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
CR20140135A (en) NEW DERIVATIVES OF ARIL-QUINOLINA